Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Immune characterization and biomarker discovery to guide treatment decisions in muscle invasive bladder cancer

FY 2023-24

Summary
Our study aims to improve treatment decisions for muscle invasive bladder cancer, a disease affecting about one-third of bladder cancer patients. Despite recent therapeutic advancements, not all patients respond to available therapies. We lack reliable markers to guide treatment, particularly in advanced cases. We plan to use advanced imaging techniques to study the environment surrounding a tumor at a cellular level, focusing on immune cells and their interactions. First, we want to assess if the number and arrangement of immune cells around a tumor can predict how patients respond to certain treatments. Second, we aim to understand how treatments impact the environment. To achieve this, we'll analyze data from four carefully curated patient datasets, using cutting-edge technology called multiplex immunofluorescence (mIF). This technique allows us to examine the tumor environment at a detailed, single-cell level to identify and classify immune cells. We'll calculate the abundance and density of these cells and explore their spatial relationships, considering the distances and proximities to each other. We'll compare these features between groups of patients who received different treatments and before and after treatment to better understand why some treatments might fail depending on these features. Our study's expected outcomes are to deepen our understanding of how treatments interact with the tumor environment and why certain patients don't respond well to treatment. By identifying specific patterns in the tumor environment, we aim to develop signatures that can help predict which patients will benefit from particular therapies. This could lead to more personalized and effective treatment strategies for bladder cancer, ultimately improving patient outcomes.
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
505845
Name
Alabi Nikolay
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Immune characterization and biomarker discovery to guide treatment decisions in muscle invasive bladder cancer
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bladder Cancer; Immunology; Precision Oncology
Abstract
Our study aims to improve treatment decisions for muscle invasive bladder cancer, a disease affecting about one-third of bladder cancer patients. Despite recent therapeutic advancements, not all patients respond to available therapies. We lack reliable markers to guide treatment, particularly in advanced cases. We plan to use advanced imaging techniques to study the environment surrounding a tumor at a cellular level, focusing on immune cells and their interactions. First, we want to assess if the number and arrangement of immune cells around a tumor can predict how patients respond to certain treatments. Second, we aim to understand how treatments impact the environment. To achieve this, we'll analyze data from four carefully curated patient datasets, using cutting-edge technology called multiplex immunofluorescence (mIF). This technique allows us to examine the tumor environment at a detailed, single-cell level to identify and classify immune cells. We'll calculate the abundance and density of these cells and explore their spatial relationships, considering the distances and proximities to each other. We'll compare these features between groups of patients who received different treatments and before and after treatment to better understand why some treatments might fail depending on these features. Our study's expected outcomes are to deepen our understanding of how treatments interact with the tumor environment and why certain patients don't respond well to treatment. By identifying specific patterns in the tumor environment, we aim to develop signatures that can help predict which patients will benefit from particular therapies. This could lead to more personalized and effective treatment strategies for bladder cancer, ultimately improving patient outcomes.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Alabi, Nikolay
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~